CDKN2A and cancer: Some reports in the literature connect the expression of p16 with a lack of progression to cancer from precancerous lesions [31], a trend toward better survival in RT-treated patients [17], a longer relapse-free survival (RFS) [14,32], and in a recent paper a significant impact both on disease-specific survival and overall survival in surgically treated patients [33].